ID Source | ID |
---|---|
PubMed CID | 73196 |
SCHEMBL ID | 243295 |
MeSH ID | M0064430 |
Synonym |
---|
(quinolin-2-yl)methanol |
EN300-14249 |
.alpha.-quinaldinol |
2-(hydroxymethyl)quinoline |
1780-17-2 |
2-quinolinemethanol |
nsc-6506 |
nsc6506 |
OPREA1_400255 |
2-quinolylmethanol |
AKOS000278553 |
quinolin-2-ylmethanol |
HMS1744C20 |
2-quinolinylmethanol |
quinolin-2-yl-methanol |
2-hydroxymethylquinoline |
einecs 217-225-7 |
alpha-quinaldinol |
nsc 6506 |
FT-0612625 |
BL002914 |
SCHEMBL243295 |
quinolinylmethanol |
hydroxymethylquinoline |
2-quinolinylmethanol # |
quinolinemethanol |
PS-8787 |
AC-26522 |
CS-0044957 |
DTXSID60170410 |
J-510324 |
2-quinolinylmethanol, aldrichcpr |
mfcd00086626 |
2,2-bithiophene-5,5-dicarboxylicacid |
Q63408719 |
AMY24777 |
quinoline-2-methanol |
SB67545 |
SY064549 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (60.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |